MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma

MolDx provides limited coverage for DNA/RNA molecular assays to aid diagnosis of cutaneous melanoma when all conditions are met: ordered by a board-certified/board-eligible dermatopathologist; specimen is a primary non-metastatic non-re-excision cutaneous melanocytic lesion with equivocal diagnosis after standard and ancillary testing; specimen contains a representative suspicious area; and the patient has not been previously tested. The assay must be validated for the intended-use population, demonstrate analytical and clinical validity and clinical utility, and undergo a MolDx technical assessment; tests failing these requirements or used outside the stated conditions (including metastatic or re-excision specimens or prior identical testing) are not covered.

"Test is ordered by a board-certified or board-eligible dermatopathologist."

Sign up to see full coverage criteria, indications, and limitations.